ReviewDiscover oncology2026
The impact of lipid metabolism remodeling in the tumor microenvironment on angiogenesis.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour cells enhance their survival and proliferation through autocrine and paracrine signalling, thereby facilitating tumour progression. Sustained growth requires the formation of new blood vessels, making angiogenesis a major therapeutic target. Concurrently, tumour development involves metabolic reprogramming to support uncontrolled proliferation. While the role of tumour metabolism in immune regulation has been widely studied, its contribution to angiogenesis remains less understood.
objectiveTo summarize current knowledge on how tumour-driven lipid metabolic reprogramming influences angiogenesis within the tumour microenvironment (TME) and to identify potential therapeutic opportunities.
methodsWe reviewed recent studies focusing on the intersection between tumour lipid metabolism and angiogenesis, integrating findings from experimental and translational research.
resultsEmerging evidence indicates that lipid metabolic alterations in tumour cells modulate endothelial function, vascular remodelling, and pro-angiogenic signalling pathways. These changes reshape the angiogenic landscape of the TME, contributing to tumour progression and therapy resistance.
conclusionUnderstanding the interplay between lipid metabolism and angiogenesis may uncover novel therapeutic vulnerabilities. Targeting metabolic reprogramming in the TME could provide new avenues for anti-angiogenic strategies and improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.